[HTML][HTML] Diagnostic biomarkers of amyloid and tau pathology in Alzheimer's disease: an overview of tests for clinical practice in the United States and Europe

L Iaccarino, SC Burnham, G Dell'Agnello… - The Journal of …, 2023 - Elsevier
Amyloid and tau biomarkers for Alzheimer's disease are widely recognized diagnostic tools
for the identification of Alzheimer's disease pathology antemortem and are recommended by …

[HTML][HTML] Diagnostic biomarkers in Alzheimer's disease

E Andersen, B Casteigne, WD Chapman… - Biomarkers in …, 2021 - Elsevier
In this review article we examine the various types of diagnostic biomarkers which are used
in the early detection of Alzheimer's disease. This review summerizes the A/T/N …

Tau PET correlates with different Alzheimer's disease‐related features compared to CSF and plasma p‐tau biomarkers

R Ossenkoppele, J Reimand, R Smith… - EMBO molecular …, 2021 - embopress.org
PET, CSF and plasma biomarkers of tau pathology may be differentially associated with
Alzheimer's disease (AD)‐related demographic, cognitive, genetic and neuroimaging …

Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy

MJ Grothe, A Moscoso, NJ Ashton, TK Karikari… - Neurology, 2021 - AAN Enterprises
Objective To study CSF biomarkers of Alzheimer disease (AD) analyzed by fully automated
Elecsys immunoassays compared to neuropathologic gold standards and to compare their …

Evaluation of plasma biomarkers for a/T/N classification of Alzheimer disease among adults of Caribbean Hispanic ethnicity

LS Honig, MS Kang, AJ Lee… - JAMA Network …, 2023 - jamanetwork.com
Importance Cerebrospinal fluid (CSF) and plasma biomarkers can detect biological
evidence of Alzheimer disease (AD), but their use in low-resource environments and among …

Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction

E Düzel, G Ziegler, D Berron, A Maass, H Schütze… - Brain, 2022 - academic.oup.com
We investigated whether the impact of tau-pathology on memory performance and on
hippocampal/medial temporal memory function in non-demented individuals depends on …

Direct to Consumer Biomarker Testing for Alzheimer Disease—Are We Ready for the Insurance Consequences?

JJ Arias, M Manchester, J Lah - JAMA neurology, 2024 - jamanetwork.com
QuestDiagnosticsintroducedthefirst-to-marketdirectto-consumer (DTC) biomarker test for
Alzheimer disease (AD) on July 31, 2023. The test provides consumers a blood draw at the …

Neuroimaging phenotypes of CSF1R‐related leukoencephalopathy: Systematic review, meta‐analysis, and imaging recommendations

GC Mickeviciute, M Valiuskyte, M Plattén… - Journal of Internal …, 2022 - Wiley Online Library
Colony‐stimulating factor 1 receptor (CSF1R)‐related leukoencephalopathy is a rare but
fatal microgliopathy. The diagnosis is often delayed due to multifaceted symptoms that can …

Development of SERS Active Nanoprobe for Selective Adsorption and Detection of Alzheimer's Disease Biomarkers Based on Molecular Docking

UC Garnaik, A Chandra, VK Goel… - International Journal …, 2024 - Taylor & Francis
Purpose Development of SERS-based Raman nanoprobes can detect the misfolding of
Amyloid beta (Aβ) 42 peptides, making them a viable diagnostic technique for Alzheimer's …

Cardiovascular dysautonomia and cognitive impairment in Parkinson's disease

I Khalil, R Sayad, AM Kedwany… - Medicine …, 2024 - spandidos-publications.com
Cognitive impairment is a prevalent non-motor symptom of Parkinson's disease (PD), which
can result in significant disability and distress for patients and caregivers. There is a marked …